Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN10A | Q9Y5Y9 | 6/20 | 0.56 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.56 |
| ▸ | SCN5A | Q14524 | 5/20 | 0.56 |
| ▸ | SCN1A | P35498 | 1/20 | 0.56 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.56 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.56 |
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.56 |
| ▸ | F2RL3 | Q96RI0 | 1/20 | 0.41 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.41 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.41 |
| ▸ | CDK2 | P24941 | 1/20 | 0.41 |
| ▸ | CDK9 | P50750 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | ACP1 | P24666 | 1/20 | 0.40 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.40 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17518813 | 0.79 | SCN5A (0.47) | SCN10AKCNH2SCN5ASCN1ASCN9A | |
| SCHEMBL1859703 | 0.79 | XDH (0.47) | SCN10AKCNH2SCN5ASCN1ASCN9A | |
| SCHEMBL1928313 | 0.77 | AKT1 (0.40) | ADORA3KDM4EMAPTNPC1ALDH1A1 | |
| SCHEMBL19558100 | 0.75 | SCN5A (0.41) | SCN10AKCNH2SCN5ASCN1ASCN9A | |
| SCHEMBL3401143 | 0.74 | CCNT1 (0.43) | SCN10AKCNH2SCN5ASCN1ASCN9A | |
| SCHEMBL9080400 | 0.73 | KDM4E (0.49) | KDM4EGAAMAPTNPC1ALDH1A1 | |
| SCHEMBL26096161 | 0.72 | GRK6 (0.39) | SCN10ASCN5ASCN9AF2RL3CCNT1 | |
| SCHEMBL15244713 | 0.71 | KDM1A (0.49) | F2RL3CCNT1CCNA2CDK2CDK9 | |
| SCHEMBL26464281 | 0.71 | TRPV1 (0.41) | SCN10AKCNH2SCN5ASCN1ASCN9A | |
| SCHEMBL26464150 | 0.71 | ALOX5 (0.50) | SCN5ACCNT1CCNA2CDK2CDK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240398762-A1 | PHARMACEUTICAL COMPOSITION WITH ANALGESIC AND/OR ANTIPRURITIC FUNCTIONS AND APPLICATION THEREOF | KEVICI (SHANGHAI) PHARMACEUTICAL CO., LTD. (CN) | 2024-12-05 | — | — | US | disclosed |
| EP-4464319-A1 | PHARMACEUTICAL COMPOSITION HAVING ANALGESIC AND/OR ANTIPRURITIC FUNCTION AND USE THEREOF | Pengekiphen Biotech Limited Company (CN) | 2024-11-20 | — | — | EP | disclosed |
| WO-2023155837-A1 | PHARMACEUTICAL COMPOSITION HAVING ANALGESIC AND/OR ANTIPRURITIC FUNCTION AND USE THEREOF | 昆山彭济凯丰生物科技有限公司 | 2023-08-24 | — | — | WO | disclosed |
| US-11221329-B2 | Treatment of neurological and neurodevelopmental diseases and disorders associated with aberrant ion channel expression and activity | LIEBER INSTITUTE, INC. (US) | 2022-01-11 | — | — | US | disclosed |
| US-11221329-B2 | Treatment of neurological and neurodevelopmental diseases and disorders associated with aberrant ion channel expression and activity | LIEBER INSTITUTE, INC. (US) | 2022-01-11 | — | — | US | disclosed |
| US-20180328915-A1 | Treatment of Neurological and Neurodevelopmental Diseases and Disorders Associated with Aberrant Ion Channel Expression and Activity | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2018-11-15 | — | — | US | disclosed |
| WO-2017075222-A1 | TREATMENT OF NEUROLOGICAL AND NEURODEVELOPMENTAL DISEASES AND DISORDERS ASSOCIATED WITH ABERRANT ION CHANNEL EXPRESSION AND ACTIVITY | LIEBER INSTITUTE FOR BRAIN DEVELOPMENT (US) | 2017-05-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11221329-B2 | Treatment of neurological and neurodevelopmental diseases and disorders associated with aberrant ion channel expression and activity | KCNQ1, KCNQ2, KCNQ3 | SCN10A 11/4885KCNH2 72/4885SCN5A 48/4885 |
| US-20240398762-A1 | PHARMACEUTICAL COMPOSITION WITH ANALGESIC AND/OR ANTIPRURITIC FUNCTIONS AND APPLICATION THEREOF | SCN7A, SCN8A, SCNN1G | SCN10A 7/4885KCNH2 65/4885SCN5A 9/4885 |
| US-20180328915-A1 | Treatment of Neurological and Neurodevelopmental Diseases and Disorders Associated with Aberrant Ion Channel Expression and Activity | KCNQ1, KCNQ2, KCNQ3 | SCN10A 11/4885KCNH2 72/4885SCN5A 48/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.